[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341757-105":59,"doc-detail-341757-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","pharmacologic-ldh-inhibition-redirects-intratumoral-glucose-uptake-and-improves-antitumor-immunity-in-solid-tumor-models","Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models","","LDH inhibition is investigated as a strategy to re-balance glucose availability for T cells in the tumor microenvironment. Tumor glycolysis is described as a hallmark of cancer and a resistance mechanism for immunotherapy, driven by lactate production and reduced glucose access for immune cells. In preclinical solid tumor models, LDH inhibitors reduce tumor glucose uptake, GLUT1 expression, and proliferation while increasing glucose uptake, GLUT1 expression, and proliferation of tumor-infiltrating T cells. The approach also weakens Treg-mediated suppression in vitro and, combined with immune checkpoint blockade, controls melanoma and colon cancer by promoting effector T-cell infiltration and activation.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pharmacologic-ldh-inhibition-redirects-intratumoral-glucose-uptake-and-improves-antitumor-immunity-in-solid-tumor-models/341757/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pharmacologic-ldh-inhibition-redirects-intratumoral-glucose-uptake-and-improves-antitumor-immunity-in-solid-tumor-models/341757.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",16,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How does LDH inhibition affect glucose availability inside tumors?","Question",{"text":113,"@type":114},"LDH inhibitors decrease tumor cell glucose uptake and GLUT1 expression while increasing glucose uptake and GLUT1 expression in tumor-infiltrating T cells, improving T-cell access to glucose within the tumor microenvironment.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What impact does LDH inhibition have on tumor-infiltrating immune cells?",{"text":118,"@type":114},"LDH inhibition increases glucose uptake, GLUT1 expression, and proliferation of tumor-infiltrating T cells, while impairing Treg immunosuppressive activity in vitro.",{"name":120,"@type":111,"acceptedAnswer":121},"Why does combining LDH inhibition with immune checkpoint blockade improve outcomes?",{"text":122,"@type":114},"The combination promotes effector T-cell infiltration and activation and destabilizes Tregs, effectively controlling progression of murine melanoma and colon cancer models.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},341757,1790168116,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","The Journal of Clinical Investigation RESEAR CH ARTICLE  \nPharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models  \nSvena Verma,1,2,3 Sadna Budhu,1,2,3 Inna Serganova,3,4 Lauren Dong,1,2,3 Levi M. Mangarin,2,3 Jonathan F. Khan,1,2,3 Mamadou A. Bah,2,3,5 Anais Assouvie,2,3 Yacine Marouf,2,3 Isabell Schulze,2,3 Roberta Zappasodi,3,4,5 Jedd D. Wolchok,2,3,4,5,6 and Taha Merghoub1,2,3,6 1Pharmacology Program, 2Swim Across America, and Ludwig Collaborative Laboratory, Department of Pharmacology, 3Sandra and Edward Meyer Cancer Center, 4Department of Medicine, 5Immunology and Microbial Pathogenesis Program, 6Parker Institute for Cancer Immunotherapy, Weill Cornell Medicine, New York, New York, USA.  \nTumor reliance on glycolysis is a hallmark of cancer. Immunotherapy is more effective in controlling glycolysis-low tumors lacking lactate dehydrogenase (LDH) due to reduced tumor lactate efflux and enhanced glucose availability within the tumor microenvironment (TME). LDH inhibitors (LDHi) reduce glucose uptake and tumor growth in preclinical models, but their impact on tumor-infiltrating T cells is not fully elucidated. Tumor cells have higher basal LDH expression and glycolysis levels compared with infiltrating T cells, creating a therapeutic opportunity for tumor-specific targeting of glycolysis. We demonstrate that LDHi treatment (a) decreases tumor cell glucose uptake, expression of the glucose transporter GLUT1, and tumor cell proliferation while (b) increasing glucose uptake, GLUT1 expression, and proliferation of tumor-infiltrating T cells. Accordingly, increasing glucose availability in the microenvironment via LDH inhibition leads to improved tumor-killing T cell function and impaired Treg immunosuppressive activity in vitro. Moreover, combining LDH inhibition with immune checkpoint blockade therapy effectively controls murine melanoma and colon cancer progression by promoting effector T cell infiltration and activation while destabilizing Tregs. Our results establish LDH inhibition as an effective strategy for rebalancing glucose availability for T cells within the TME, which can enhance T cell function and antitumor immunity.  \nIntroduction  \nThe Warburg effect describes the propensity of cancer cells to favor the conversion of glucose to lactate for energy production, even in the presence of oxygen (1, 2). In this process, glucose is rapidly consumed and converted to pyruvate, which is then diverted from oxidative phosphorylation to lactate production through the activity of the enzyme lactate dehydrogenase (LDH) (3, 4). Over the last century, scientists have expanded upon this phenomenon and deemed altered tumor metabolism a major hallmark of cancer (5, 6). Preferential engagement in glycolysis contributes to the growth, progression, and metastasis of many tumor types, including melanoma, colon cancer, and triple-negative breast cancer (TNBC). Therefore, glycolysis constitutes an attractive pathway to target in cancer therapy (6–9). Tumor cells’ reliance on glycolysis is also a well-documented mechanism of resistance to immunotherapy, including immune checkpoint blockade (ICB) (8, 10–12). Antitumor immune cell activity within the tumor is affected by lactate-mediated acidification. In addition, immune cells in the tumor microenvironment (TME) must compete for glucose with glycolytic tumor cells (13–15).  \nConflict of interest: The conflict-of-interest statement is available in the Supplemental Material.  \nCopyright: © 2024, Verma et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.  \nSubmitted: November 14, 2023; Accepted: June 4, 2024; Published: September 3, 2024.  \nReference information: J Clin Invest. 2024;134(17):e177606 .  \n[https://doi.org/10.1172/JCI177606](https://doi.org/10.1172/JCI177606) .  \nSeveral studies have advocated for targeting glycolytic proteins in combination wit","cbCailLMvHrWmL5C","https://ap.wps.com/l/cbCailLMvHrWmL5C","pdf",6904647,14,"English","# Introduction\n## Warburg effect and glycolysis in tumor immunity\n## Metabolic competition in the tumor microenvironment\n# LDH targeting rationale\n## LDH isoforms and differential expression\n## Limitations of prior glycolysis-targeting approaches\n# Results overview\n## Effects on tumor glucose uptake and GLUT1\n## Effects on tumor-infiltrating T cells\n## Combination with immune checkpoint blockade","[{\"question\":\"How does LDH inhibition affect glucose availability inside tumors?\",\"answer\":\"LDH inhibitors decrease tumor cell glucose uptake and GLUT1 expression while increasing glucose uptake and GLUT1 expression in tumor-infiltrating T cells, improving T-cell access to glucose within the tumor microenvironment.\"},{\"question\":\"What impact does LDH inhibition have on tumor-infiltrating immune cells?\",\"answer\":\"LDH inhibition increases glucose uptake, GLUT1 expression, and proliferation of tumor-infiltrating T cells, while impairing Treg immunosuppressive activity in vitro.\"},{\"question\":\"Why does combining LDH inhibition with immune checkpoint blockade improve outcomes?\",\"answer\":\"The combination promotes effector T-cell infiltration and activation and destabilizes Tregs, effectively controlling progression of murine melanoma and colon cancer models.\"}]","Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models | PDF",1790043590,35,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dedebc3503aa501adab686986a5a97a6.webp",983,1315,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/02c5a391dea16f92883222039a7b3205.webp",982,1314,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bcf4033148d2dbad50adc919a2531c90.webp",981,1312,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fda2ef92e62d64703230755b45523b92.webp",980,1311]